Use of interleukin-17 receptor antagonists in the treatment of psoriasis: Analysis of clinical studies, treatment outcomes, and potential side effects

Authors

  • Maria Ivanova Ural State Medical University, 3, ul. Repina, Yekaterinburg, 620028, Russian Federation
  • Yulia Chukhrai Ural State Medical University, 3, ul. Repina, Yekaterinburg, 620028, Russian Federation
  • Anastasia Kuznetsova Saratov State Medical University named after V. I. Razumovsky, 112, ul. Bolshaya Kazachya, Saratov, 410012, Russian Federation https://orcid.org/0009-0009-2478-1079
  • Kristina Sukhanova Saint Petersburg State Pediatric Medical University, 2, ul. Litovskaya, St. Petersburg, 194100, Russian Federation https://orcid.org/0009-0007-1569-6855
  • Victoria Blaschenko Russian National Research Medical University, 10, ul. Lenina, Moscow, 123456, Russian Federation https://orcid.org/0009-0009-6120-5724

DOI:

https://doi.org/10.21638/spbu11.2024.401

Abstract

Psoriasis is a skin disease affecting 2–3 % of the global population, characterized by epidermal hyperplasia and inflammation. This condition significantly deteriorates patients’ quality of life due to physical discomfort, psychological issues, and social stigmatization. Current treatment options include topical agents, phototherapy, systemic drugs, and biologics; however, their effectiveness remains limited. In this context, the efficacy and safety of interleukin-17 receptor antagonists, which play a key role in psoriasis pathogenesis, are under investigation. This article analyzes clinical studies evaluating the efficacy of receptor antagonists, such as secukinumab, ixekizumab, and brodalumab, and their impact on symptom improvement and patients’ quality of life. Interleukin-17 antagonists block key inflammatory signaling pathways, as evidenced by reductions in Psoriasis Area and Severity Index and Dermatology Life Quality Index scores. Differences in the mechanisms of action of secukinumab, ixekizumab, and brodalumab determine their specific clinical applications and safety profiles. The analysis highlights the significant clinical relevance of interleukin-17 antagonists for patients with moderate-to-severe psoriasis, especially in cases where traditional treatments are insufficient. Careful monitoring of side effects and further research will help optimize approaches to psoriasis therapy, ensuring the safest and most effective treatment for patients

Keywords:

psoriasis, IL-17, secukinumab, ixekizumab, brodalumab, biological agents, inflammation, quality of life

Downloads

Download data is not yet available.
 

References

Литература

Адильгереева М. И. Аспекты возникновения псориаза // Ученый XXI века. 2022. № 8 (89). С. 11–15.

Аликбаев Т. З., Фролова Е. В., Гулордава М. Д., Максимова М. Д., Учеваткина А. Е., Филиппова Л. В., Васильева Н. В., Разнатовский К. И. Современные представления о патогенезе, клинике и течении тяжелого псориаза // Проблемы медицинской микологии. 2021. Т. 23, № 4. С. 9–16.

Brembilla N. C., Boehncke W. H. Revisiting the interleukin 17 family of cytokines in psoriasis: Pathogenesis and potential targets for innovative therapies // Front. Immunol. 2023. Vol.14. P. 1186455. https://doi.org/10.3389/fimmu.2023.1186455

Guo J., Zhang H., Lin W., Lu L., Su J., Chen X. Signaling pathways and targeted therapies for psoriasis// Signal Transduct. Target Ther. 2023. Vol. 8, no. 1. P. 437. https://doi.org/10.1038/s41392-023-01655-6

Cai Y., Xue F., Quan C., Qu M., Liu N., Zhang Y., Fleming C., Hu X., Zhang H. G., Weichselbaum R., Fu Y. X., Tieri D., Rouchka E. C., Zheng J., Yan J. A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis // J. Invest. Dermatol. 2019. Vol. 139, no. 1. P. 146–156. https://doi.org/10.1016/j.jid.2018.07.025

Tomar Y., Gorantla S., Singhvi G. Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches // Drug Discov. Today. 2023. Vol. 28, no. 2. P. 103465. https://doi.org/10.1016/j.drudis.2022.103465

Сарсур Ш. Х. Р., Руднева Н. С. Возможности биологической терапии при псориазе // Вестник СурГУ. Медицина. 2022. № 4 (54). С. 13–20. https://doi.org/10.34822/2304-9448-2022-4-13-20

Андреев Д. А., Камынина Н. Н. Свойства и применение дерматологического индекса оценки качества жизни у пациентов с псориазом // Здоровье мегаполиса. 2023. Т. 4, № 4. С. 122–134.

Рысбекова Д. Е., Бейсебаева У. Т., Машкунова О. В., Альменова Л. Т., Бегимжанова Б. К., Колбаев М. Т., Ахтаева Н. С. Корреляционная связь между качеством жизни и тяжестью течения псориаза // Вестник КазНМУ. 2020. № 1. С. 75–81.

Котрехова Л. П. На какой результат рассчитывают врач и пациент при терапии псориаза// Consilium Medicum. 2020. Т. 22, № 7. С. 25–28. https://doi.org/10.26442/20751753.2020.7.200313

Kiltz U., Sfikakis P. P., Gaffney K., Sator P. G., von Kiedrowski R., Bounas A., Gullick N., Conrad C.,Rigopoulos D., Lespessailles E., Romanelli M., Ghislain P. D., Brandt-Jürgens J., Rashkov R., Aassi M., Orsenigo R., Perella C., Pournara E., Gathmann S., Jagiello P., Veit J., Augustin M. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: Baseline data from SERENA study // Adv. Ther. 2020. Vol. 37, no. 6. P. 2865–2883. https://doi.org/10.1007/s12325-020-01352-8

Deodhar A., Mease P. J., McInnes I. B., Baraliakos X., Reich K., Blauvelt A., Leonardi C., Porter B., Das Gupta A., Widmer A., Pricop L., Fox T. Long-term safety of secukinumab in patients with moder-ate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data // Arthritis Res. Ther. 2019. Vol. 21, no. 1. P. 111. https://doi.org/10.1186/s13075-019-1882-2

Wasel N., Thaçi D., French L. E., Conrad C., Dutronc Y., Gallo G., Berggren L., Lacour J. P. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-weekresults from a phase 3, head-to-head study (IXORA-S) // Dermatol. Ther. (Heidelb). 2020. Vol.10,

Deodhar A. A., Combe B., Accioly A. P., Bolce R., Zhu D., Gellett A. M., Sprabery A. T., Burmester G. R.Safety of ixekizumab in patients with psoriatic arthritis: Data from four clinical trials with over 2000 patient-years of exposure // Ann. Rheum. Dis. 2022. Vol.81, no. 7. P.944–950. https://doi.org/10.1136/annrheumdis-2021-222027

Menter A., Armstrong A., Van Voorhees A., Liu C., Jacobson A. Brodalumab to the rescue: Efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics// Dermatol. Ther. (Heidelb). 2020. Vol. 10, no. 4. P. 615–621. https://doi.org/10.1007/s13555-020-00411-w


References

Adilgereyeva M. I. Aspects of psoriasis onset. Uchenyi XXI veka, 2022, no. 8 (89), pp. 11–15. (In Russian)

Alikbaev T. Z., Frolova E. V., Gulordava M. D., Maksimova M. D., Uchevatkina A. E., Filippova L. V.,Vasilieva N. V., Raznatovsky K. I. Modern concepts of pathogenesis, clinic, and course of severe psoriasis. Problemy meditsinskoy mikologii, 2021, vol. 23, no. 4, pp. 9–16. (In Russian)

Brembilla N. C., Boehncke W. H. Revisiting the interleukin-17 family of cytokines in psoriasis: Pathogenesis and potential targets for innovative therapies. Front. Immunol., 2023, vol. 14, 1186455 p.https://doi.org/10.3389/fimmu.2023.1186455

Guo J., Zhang H., Lin W., Lu L., Su J., Chen X. Signaling pathways and targeted therapies for psoriasis.Signal Transduct. Target Ther., 2023, vol. 8, no. 1, 437 p. https://doi.org/10.1038/s41392-023-01655-6

Cai Y., Xue F., Quan C., Qu M., Liu N., Zhang Y., Fleming C., Hu X., Zhang H. G., Weichselbaum R.,Fu Y. X., Tieri D., Rouchka E. C., Zheng J., Yan J. A critical role of the IL-1β-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J. Invest. Dermatol., 2019, vol. 139, no. 1, pp. 146–156. https://doi.org/10.1016/j.jid.2018.07.025

Tomar Y., Gorantla S., Singhvi G. Insight into the pivotal role of signaling pathways in psoriasis patho-genesis, potential therapeutic molecules and drug delivery approaches. Drug Discov. Today, 2023, vol. 28, no. 2, p. 103465. https://doi.org/10.1016/j.drudis.2022.103465

Sarsur Sh. Kh. R., Rudneva N. S. Opportunities for biological therapy in psoriasis.Vestnik SurGU. Medicina, 2022, no. 4 (54), pp. 13–20. https://doi.org/10.34822/2304-9448-2022-4-13-20 (In Russian)

Andreev D. A., Kamynina N. N. Properties and application of the dermatological life quality index in patients with psoriasis. Zdorov’e megapolisov, 2023, vol. 4, no. 4, pp. 122–134. (In Russian))

Rysbekova D. E., Beisebayeva U. T., Mashkunova O. V., Almenova L. T., Begimzhanova B.K., Kolbaev M. T., Akhtaeva N. S. Correlation between quality of life and severity of psoriasis. Vestnik KazNMU, 2020, no. 1. pp. 75–81. (In Russian)

Kotrekhova L. P. What result do the doctor and patient expect in psoriasis therapy. Consilium Medicum, 2020, vol. 22, no. 7, pp. 25–28. https://doi.org/10.26442/20751753.2020.7.200313 (In Russian))

Kiltz U., Sfikakis P. P., Gaffney K., Sator P. G., von Kiedrowski R., Bounas A., Gullick N., Conrad C.,Rigopoulos D., Lespessailles E., Romanelli M., Ghislain P. D., Brandt-Jürgens J., Rashkov R., Aassi M., Orsenigo R., Perella C., Pournara E., Gathmann S., Jagiello P., Veit J., Augustin M. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: Baseline data from SERENA study. Adv. Ther., 2020, vol. 37, no. 6, pp. 2865–2883. https://doi.org/10.1007/s12325-020-01352-8

Deodhar A., Mease P. J., McInnes I. B., Baraliakos X., Reich K., Blauvelt A., Leonardi C., Porter B., Das Gupta A., Widmer A., Pricop L., Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res. Ther., 2019, vol. 21, no. 1, p. 111. https://doi.org/10.1186/s13075-019-1882-2

Wasel N., Thaçi D., French L. E., Conrad C., Dutronc Y., Gallo G., Berggren L., Lacour J. P. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol. Ther. (Heidelb.), 2020, vol. 10, no. 4, pp. 663–670. https://doi.org/10.1007/s13555-020-00383-x

Deodhar A. A., Combe B., Accioly A. P., Bolce R., Zhu D., Gellett A. M., Sprabery A. T., Burmester G. R. Safety of ixekizumab in patients with psoriatic arthritis: Data from four clinical trials with over 2000 patient-years of exposure. Ann. Rheum. Dis., 2022, vol. 81, no. 7, pp. 944–950. https://doi.org/10.1136/annrheumdis-2021-222027

Menter A., Armstrong A., Van Voorhees A., Liu C., Jacobson A. Brodalumab to the rescue: Efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics. Dermatol. Ther. (Heidelb.), 2020, vol. 10, no. 4, pp. 615–621. https://doi.org/10.1007/s13555-020-00411-w

Downloads

Published

2025-04-21

How to Cite

Ivanova, M., Chukhrai, Y., Kuznetsova, A., Sukhanova, K., & Blaschenko, V. (2025). Use of interleukin-17 receptor antagonists in the treatment of psoriasis: Analysis of clinical studies, treatment outcomes, and potential side effects. Vestnik of Saint Petersburg University. Medicine, 19(4), 300–310. https://doi.org/10.21638/spbu11.2024.401

Issue

Vol. 19 No. 4 (2024)

Section

Internal medicine

License

Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.